Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-05-05 | New | $7,000,000 | $7,000,000 | Equity Only | 06b | SEC link |
| 2024-03-18 | New | $75,000,000 | $75,000,000 | Equity Only | 06b | SEC link |
| 2021-01-20 | New | $499,618 | $499,618 | Equity Only | 06b | SEC link |
| 2020-12-22 | New | $78,268 | $78,268 | Equity Only | 06b | SEC link |
| 2020-11-13 | New | $247,705 | $247,705 | Equity Only | 06b | SEC link |
| 2020-06-08 | New | $468,248 | $468,248 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Robert Barrow | Director, Executive |
| Suzanne Bruhn | Director |
| Roger Crystal | Director |
| Perry Dellelce | Director |
| Stanley Glick | Director |
| Schond Greenway | Executive |
| David Gryska | Director |
| Stephen Hurst | Director, Executive |
| Daniel Karlin | Executive |
| Andreas Krebs | Director |
| Carrie Liao | Executive |
| Bruce Linton | Director |
| Brigid Makes | Director |
| Jamon Alexander Rahn | Director, Executive |
| Jamon Alexander Rahn | Director, Executive |
| Mark R. Sullivan | Executive |
| Carol A. Vallone | Director |
| Miri Halperin Wernli | Executive |
| Miriam Halperin Wernli | Director, Executive |
| Miriam Halperin Wernli | Director, Executive |
| Matt Wiley | Executive |